Loading...

Allergan

NYSE:AGN
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AGN
NYSE
$53B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The last earnings update was 78 days ago. More info.


Add to Portfolio Compare Print
  • Allergan has significant price volatility in the past 3 months.
AGN Share Price and Events
7 Day Returns
-0.4%
NYSE:AGN
-1.6%
US Pharmaceuticals
-0.9%
US Market
1 Year Returns
-8.4%
NYSE:AGN
3.3%
US Pharmaceuticals
3.8%
US Market
AGN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Allergan (AGN) -0.4% 24.9% 14.4% -8.4% -37.8% -24.9%
US Pharmaceuticals -1.6% -4.8% -0.9% 3.3% -0.4% 12%
US Market -0.9% 1.1% 1.1% 3.8% 35.5% 42.1%
1 Year Return vs Industry and Market
  • AGN underperformed the Pharmaceuticals industry which returned 3.3% over the past year.
  • AGN underperformed the Market in United States of America which returned 3.8% over the past year.
Price Volatility
AGN
Industry
5yr Volatility vs Market

Value

 Is Allergan undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Allergan to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Allergan.

NYSE:AGN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 18 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NYSE:AGN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 7.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 12.5%) (45.33%))
1.015
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.02
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.015 * 7.14%)
9.98%

Discounted Cash Flow Calculation for NYSE:AGN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Allergan is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NYSE:AGN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.98%)
2020 5,837.10 Analyst x5 5,307.51
2021 6,046.14 Analyst x5 4,998.80
2022 6,157.34 Analyst x5 4,628.87
2023 6,357.62 Analyst x5 4,345.80
2024 6,531.82 Est @ 2.74% 4,059.79
2025 6,710.59 Est @ 2.74% 3,792.48
2026 6,894.12 Est @ 2.73% 3,542.71
2027 7,082.56 Est @ 2.73% 3,309.34
2028 7,276.09 Est @ 2.73% 3,091.31
2029 7,474.85 Est @ 2.73% 2,887.62
Present value of next 10 years cash flows $39,964.22
NYSE:AGN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $7,474.85 × (1 + 2.73%) ÷ (9.98% – 2.73%)
$105,943.84
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $105,943.84 ÷ (1 + 9.98%)10
$40,927.36
NYSE:AGN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $39,964.22 + $40,927.36
$80,891.58
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $80,891.58 / 327.82
$246.75
NYSE:AGN Discount to Share Price
Calculation Result
Value per share (USD) From above. $246.75
Current discount Discount to share price of $161.89
= -1 x ($161.89 - $246.75) / $246.75
34.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Allergan is available for.
Intrinsic value
34%
Share price is $161.89 vs Future cash flow value of $246.75
Current Discount Checks
For Allergan to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Allergan's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Allergan's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Allergan's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Allergan's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:AGN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-21.46
NYSE:AGN Share Price ** NYSE (2019-07-23) in USD $161.89
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.76x
United States of America Market PE Ratio Median Figure of 3,083 Publicly-Listed Companies 17.8x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Allergan.

NYSE:AGN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:AGN Share Price ÷ EPS (both in USD)

= 161.89 ÷ -21.46

-7.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Allergan is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Allergan is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Allergan's expected growth come at a high price?
Raw Data
NYSE:AGN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 18 Analysts
93.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.99x
United States of America Market PEG Ratio Median Figure of 2,118 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Allergan, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Allergan's assets?
Raw Data
NYSE:AGN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $187.74
NYSE:AGN Share Price * NYSE (2019-07-23) in USD $161.89
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 186 Publicly-Listed Pharmaceuticals Companies 3.09x
United States of America Market PB Ratio Median Figure of 5,249 Publicly-Listed Companies 1.78x
NYSE:AGN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:AGN Share Price ÷ Book Value per Share (both in USD)

= 161.89 ÷ 187.74

0.86x

* Primary Listing of Allergan.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Allergan is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Allergan's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Allergan has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Allergan expected to perform in the next 1 to 3 years based on estimates from 18 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
93.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Allergan expected to grow at an attractive rate?
  • Allergan's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Allergan's earnings growth is expected to exceed the United States of America market average.
  • Allergan's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NYSE:AGN Future Growth Rates Data Sources
Data Point Source Value (per year)
NYSE:AGN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 18 Analysts 93.6%
NYSE:AGN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 18 Analysts 2.5%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:AGN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:AGN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 16,943 7,089 10
2022-12-31 16,501 6,738 13
2021-12-31 16,112 6,523 1,892 16
2020-12-31 15,596 6,205 936 18
2019-12-31 15,285 5,399 -1,965 18
NYSE:AGN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 15,712 5,416 -7,218
2018-12-31 15,787 5,640 -5,143
2018-09-30 16,034 6,019 2,594
2018-06-30 16,157 6,049 -1,387
2018-03-31 16,040 6,814 -1,702
2017-12-31 15,941 6,079 -4,001
2017-09-30 15,479 3,906 -7,550
2017-06-30 15,067 1,336 -3,982
2017-03-31 14,744 916 -3,689
2016-12-31 14,571 1,446 -1,220
2016-09-30 14,313 3,091 -1,968
2016-06-30 14,161 5,237 -2,462

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Allergan's earnings are expected to grow significantly at over 20% yearly.
  • Allergan's revenue is expected to grow by 2.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:AGN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below

All data from Allergan Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:AGN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 8.80 8.80 8.80 1.00
2022-12-31 6.98 6.98 6.98 1.00
2021-12-31 4.60 6.10 3.09 2.00
2020-12-31 2.83 5.10 1.55 4.00
2019-12-31 -5.02 -2.25 -6.33 5.00
NYSE:AGN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -21.46
2018-12-31 -15.26
2018-09-30 7.72
2018-06-30 -4.15
2018-03-31 -5.10
2017-12-31 -11.99
2017-09-30 -22.20
2017-06-30 -11.22
2017-03-31 -9.97
2016-12-31 -3.17
2016-09-30 -4.99
2016-06-30 -6.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Allergan is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Allergan's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Allergan has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Allergan performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Allergan's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Allergan does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Allergan's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Allergan's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Allergan's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Allergan Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:AGN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 15,712.40 -7,218.30 4,380.00 2,216.20
2018-12-31 15,787.40 -5,142.80 4,331.20 2,253.40
2018-09-30 16,033.80 2,594.10 4,479.00 1,990.20
2018-06-30 16,156.70 -1,387.20 4,546.40 1,987.70
2018-03-31 16,039.90 -1,701.80 4,485.10 1,774.80
2017-12-31 15,940.70 -4,001.00 4,542.40 1,990.60
2017-09-30 15,478.90 -7,549.50 4,567.70 2,598.90
2017-06-30 15,066.80 -3,981.80 4,510.60 2,758.50
2017-03-31 14,744.20 -3,688.70 4,354.90 2,886.30
2016-12-31 14,570.60 -1,219.50 4,092.20 2,568.50
2016-09-30 14,313.20 -1,967.80 4,256.60 1,954.10
2016-06-30 14,160.50 -2,462.30 4,085.50 2,517.20
2016-03-31 14,104.40 -2,511.30 3,933.00 2,256.70
2015-12-31 12,688.10 -3,177.80 3,673.30 2,067.20
2015-09-30 11,496.80 -3,303.20 3,176.70 1,972.10
2015-06-30 10,178.10 -3,519.30 2,963.90 963.10
2015-03-31 6,066.80 -3,332.60 2,031.50 584.00
2014-12-31 4,676.50 -2,484.60 1,832.90 583.80
2014-09-30 7,102.60 -1,570.30 1,754.70 441.10
2014-06-30 6,964.80 -342.60 1,585.00 453.40
2014-03-31 9,437.20 -551.10 2,013.90 644.60
2013-12-31 2,602.50 -467.50 827.70 190.20
2013-09-30 7,648.50 -574.00 1,655.20 544.90
2013-06-30 6,920.70 -562.90 1,392.10 493.70
2013-03-31 6,286.10 -60.30 1,223.80 437.10
2012-12-31 5,914.90 97.30 1,171.80 402.50
2012-09-30 5,709.30 164.10 953.50 343.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Allergan has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Allergan has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Allergan improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Allergan's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Allergan has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Allergan's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Allergan's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Allergan's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Allergan's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Allergan's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Allergan Company Filings, last reported 3 months ago.

NYSE:AGN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 61,559.60 23,525.90 1,783.70
2018-12-31 65,131.00 23,790.10 1,907.30
2018-09-30 70,520.90 23,575.50 1,209.90
2018-06-30 71,264.00 25,341.10 1,696.20
2018-03-31 72,346.00 26,562.60 2,032.20
2017-12-31 73,837.10 30,072.60 6,449.30
2017-09-30 71,173.50 30,333.40 5,441.80
2017-06-30 75,232.80 30,235.70 5,825.90
2017-03-31 75,198.80 31,747.00 8,951.10
2016-12-31 76,200.50 32,766.30 13,225.50
2016-09-30 89,730.40 32,770.00 27,392.30
2016-06-30 76,640.80 39,581.70 506.60
2016-03-31 77,448.70 42,567.50 2,273.80
2015-12-31 76,589.30 42,530.40 1,105.30
2015-09-30 77,480.10 42,683.50 2,070.90
2015-06-30 72,074.50 42,870.30 1,526.40
2015-03-31 71,409.50 44,324.60 2,130.90
2014-12-31 28,335.50 15,531.10 251.00
2014-09-30 29,145.00 15,537.10 340.40
2014-06-30 9,684.70 12,331.40 4,296.10
2014-03-31 9,628.60 8,720.50 340.20
2013-12-31 9,537.10 9,052.00 331.50
2013-09-30 3,748.00 6,310.40 373.50
2013-06-30 3,541.00 6,351.10 234.90
2013-03-31 3,622.30 6,421.50 337.40
2012-12-31 3,856.40 6,433.30 328.00
2012-09-30 3,689.90 1,220.60 234.40
  • Allergan's level of debt (38.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (91% vs 38.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Allergan has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Allergan has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -27.5% per year.
X
Financial health checks
We assess Allergan's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Allergan has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Allergan's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.83%
Current annual income from Allergan dividends. Estimated to be 1.92% next year.
If you bought $2,000 of Allergan shares you are expected to receive $37 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Allergan's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
  • Allergan's dividend is below the markets top 25% of dividend payers in United States of America (3.77%).
Upcoming dividend payment

Purchase Allergan before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:AGN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:AGN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 3.30 1.00
2022-12-31 3.40 2.00
2021-12-31 3.22 5.00
2020-12-31 3.07 7.00
2019-12-31 2.96 7.00
NYSE:AGN Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-07-19 2.960 1.821
2019-05-03 2.960 2.104
2019-01-25 2.960 2.059
2018-10-26 2.880 1.897
2018-07-30 2.880 1.536
2018-05-03 2.880 1.753
2017-10-27 2.880 1.722
2017-08-02 2.800 1.306
2017-05-05 2.800 1.179
2017-02-03 2.800 1.163
2016-11-04 2.800 1.377
2016-11-02 2.800 1.445

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Allergan has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Allergan only paid a dividend in the past 3 years.
Current Payout to shareholders
What portion of Allergan's earnings are paid to the shareholders as a dividend.
  • The company is paying a dividend however it is incurring a loss.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (5.7x coverage).
X
Income/ dividend checks
We assess Allergan's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Allergan afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Allergan has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Allergan's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brent Saunders
COMPENSATION $6,624,473
AGE 49
TENURE AS CEO 5 years
CEO Bio

Mr. Brenton L. Saunders, also known as Brent, J.D., has been the Chairman of the Board at Allergan plc since October 26, 2016 and also has been its Chief Executive Officer and President since July 1, 2014. Mr. Saunders serves as the Chief Executive Officer and President of Actavis Ltd. (Alternate Name: Actavis Plc). He has significant healthcare industry expertise and led various business transformations and integrations. He has an extensive experience negotiating and implementing corporate integrity agreements with state and federal agencies. He has extensive knowledge of compliance, risk assessment, strategy and business development and extensive experience as an Officer and Director of Public Companies in the healthcare and pharmaceuticals industry. He served as the Chief Executive Officer and President of Forest Laboratories, LLC from October 1, 2013 to 2014. He served as Senior Vice President of Compliance, Legal and Regulatory at HomeCare America. He served as the Chief Executive Officer of Bausch & Lomb Incorporated from March 15, 2010 to August 2013. He served as a Special Adviser of General Atlantic LLC. He served as the President of Bausch & Lomb Holdings Incorporated from 2010 to February 2013 and also served as its Chief Executive Officer since March 15, 2010. He served as Senior Executive of Schering-Plough from 2003 to 2010 and served as its President of Global Consumer Health Care. He served as the Head of Integration for both Schering-Plough's merger with Merck & Co., Inc. He served as the President of Consumer Health Care and Senior Vice President of Schering-Plough Corporation since February 2007. He was responsible for leading the U.S. and Canadian Consumer Health Care business and works collaboratively with the Global Pharmaceutical Business unit. He served as Senior Vice President of Global Compliance and Business Practices of Schering-Plough Corporation from November 1, 2003 to February 20, 2007. He served as a Member of Executive Management Team (EMT) and Member of Operations Management Team (OMT) at Schering-Plough Corporation. His responsibilities included the development of Global Standards, Training and Enforcement Programs for Compliance in all areas of Schering Plough Corp., including manufacturing, R&D programs, clinical trials and sales and marketing. He was also responsible for the implementation of privacy policies for customers, patients, employees and other stakeholders. He joined Schering-Plough from PricewaterhouseCoopers, where he led its compliance business advisory services group. He was a Partner and Head of the Compliance Business Advisory Group at PricewaterhouseCoopers LLP from 2000 to 2003. He served as the Chief Compliance Officer of Coventry Health Care Inc. and also served as its Chief Risk Officer from 1998 to 1999. He began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. He co-founded and served as the President of the Health Care Compliance Association. He served as Senior Vice President of Compliance, Legal and Regulatory at Home Care Corporation of America. He served as Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers Malta. He co-founded Health Care Compliance Association in 1995. He has been an Independent Director of Cisco Systems, Inc. since March 13, 2017. He has been a Director of Allergan plc since July 1, 2014. He serves on the Boards of the Overlook Hospital Foundation and Actavis Funding SCS. He served as a Member of Upstate New York Regional Advisory Board at The Federal Reserve Bank of New York since June 9, 2010. He served as a Director of Forest Laboratories, LLC since August 2011. He is a natural innovator and leader with a deep understanding of business transformation. He served as a Director of Bausch & Lomb Holdings Incorporated and Bausch & Lomb Incorporated since March 15, 2010. He served as a Director of electroCore LLC. He serves as a Trustee of University of Pittsburgh. He also serves on the transition team for New Jersey Governor-Elect Chris Christie. He serves as a Member of the Business Council and PhRMA. He serves on the Board of Directors at RWJBarnabas Health. He served as the Chairman of the New York chapter of the American Heart Association. He is a noted speaker on compliance and risk management issues in the health care industry and also taught health law at Widener School of Law as an Adjunct Faculty Member. In 1997, he was named Compliance Officer of the Year at Health Care Compliance Association. Mr. Saunders has a JD from the Temple University School of Law, an MBA from the Temple University School of Business and Management and graduated with a BA in Economics from the University of Pittsburgh.

CEO Compensation
  • Brent's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Brent's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Allergan management team in years:

4.9
Average Tenure
51
Average Age
  • The tenure for the Allergan management team is about average.
Management Team

Brent Saunders

TITLE
Chairman
COMPENSATION
$7M
AGE
49
TENURE
5 yrs

Matt Walsh

TITLE
Executive VP & CFO
COMPENSATION
$11M
AGE
52
TENURE
1.4 yrs

Bob Bailey

TITLE
Executive VP
COMPENSATION
$3M
AGE
56
TENURE
5 yrs

Bill Meury

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$4M
AGE
51
TENURE
5 yrs

C. Nicholson

TITLE
Executive VP and Chief R&D Officer
COMPENSATION
$3M
AGE
64
TENURE
4.9 yrs

Wayne Swanton

TITLE
Executive Vice President of Global Operations
AGE
51
TENURE
1.6 yrs

James D'Arecca

TITLE
Chief Accounting Officer
AGE
48
TENURE
5.9 yrs

Manisha Narasimhan

TITLE
Vice President of Investor Relations & Strategic Initiatives
TENURE
0.6 yrs

Alex Kelly

TITLE
Executive VP & Chief Communications Officer
TENURE
4.3 yrs

Brent Hauser

TITLE
Vice President of Sales & Marketing
AGE
42
Board of Directors Tenure

Average tenure and age of the Allergan board of directors in years:

2.6
Average Tenure
63.5
Average Age
  • The average tenure for the Allergan board of directors is less than 3 years, this suggests a new board.
Board of Directors

Brent Saunders

TITLE
Chairman
COMPENSATION
$7M
AGE
49
TENURE
2.8 yrs

Chris Bodine

TITLE
Independent Director
COMPENSATION
$474K
AGE
63
TENURE
10.1 yrs

John Davidson

TITLE
Independent Director
COMPENSATION
$450K
AGE
64
TENURE
1.2 yrs

Tom Freyman

TITLE
Independent Director
COMPENSATION
$398K
AGE
65
TENURE
1.1 yrs

Chris Coughlin

TITLE
Lead Independent Director
COMPENSATION
$500K
AGE
67
TENURE
2.8 yrs

Nesli Basgoz

TITLE
Independent Director
COMPENSATION
$474K
AGE
61
TENURE
5 yrs

Peter McDonnell

TITLE
Independent Director
COMPENSATION
$450K
AGE
60
TENURE
4.3 yrs

Adriane Brown

TITLE
Independent Director
COMPENSATION
$450K
AGE
61
TENURE
2.4 yrs

Joe Boccuzi

TITLE
Independent Director
COMPENSATION
$450K
AGE
72
TENURE
2.5 yrs

Michael Greenberg

TITLE
Director
COMPENSATION
$331K
AGE
64
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
22. Jul 19 Sell BlackRock, Inc. Company 19. Jul 19 19. Jul 19 -7,449 $163.16 $-1,214,544
22. Jul 19 Buy BlackRock, Inc. Company 19. Jul 19 19. Jul 19 1,605 $163.16 $261,807
22. Jul 19 Sell FMR LLC Company 19. Jul 19 19. Jul 19 -115,095 $162.83 $-18,732,495
22. Jul 19 Buy FMR LLC Company 19. Jul 19 19. Jul 19 9,523 $162.67 $1,548,518
22. Jul 19 Sell Northern Trust Global Investments Company 19. Jul 19 19. Jul 19 -1,454 $163.16 $-237,235
22. Jul 19 Buy Northern Trust Global Investments Company 19. Jul 19 19. Jul 19 1,569 $163.16 $0
22. Jul 19 Sell Citadel Advisors, LLC Company 19. Jul 19 19. Jul 19 -28,939 $163.18 $-4,722,266
22. Jul 19 Buy Citadel Advisors, LLC Company 19. Jul 19 19. Jul 19 27,512 $163.18 $4,489,408
22. Jul 19 Sell T. Rowe Price Group, Inc. Company 19. Jul 19 19. Jul 19 -5 $162.62 $-813
22. Jul 19 Buy T. Rowe Price Group, Inc. Company 19. Jul 19 19. Jul 19 54 $162.89 $8,794
22. Jul 19 Buy Franklin Resources, Inc. Company 19. Jul 19 19. Jul 19 15 $162.73 $2,441
22. Jul 19 Sell Legg Mason, Inc. Company 19. Jul 19 19. Jul 19 -187 $162.39 $-30,367
22. Jul 19 Buy Legg Mason, Inc. Company 19. Jul 19 19. Jul 19 6,026 $162.70 $980,430
22. Jul 19 Sell Longview Partners (Guernsey) Ltd Company 19. Jul 19 19. Jul 19 -1,500 $163.16 $-244,740
22. Jul 19 Sell Wellington Management Group LLP Company 19. Jul 19 19. Jul 19 -161,268 $163.16 $-26,261,715
22. Jul 19 Buy Wellington Management Group LLP Company 19. Jul 19 19. Jul 19 1,032 $163.16 $168,381
22. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 18. Jul 19 18. Jul 19 337,670 $163.18 $55,100,991
22. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 19. Jul 19 19. Jul 19 457,661 $163.18 $74,683,181
19. Jul 19 Sell BlackRock, Inc. Company 18. Jul 19 18. Jul 19 -450 $162.05 $-72,923
19. Jul 19 Buy BlackRock, Inc. Company 18. Jul 19 18. Jul 19 5,924 $162.95 $960,072
19. Jul 19 Sell FMR LLC Company 18. Jul 19 18. Jul 19 -4,254 $162.79 $-689,442
19. Jul 19 Buy FMR LLC Company 18. Jul 19 18. Jul 19 15,206 $163.03 $2,475,124
19. Jul 19 Sell Citadel Advisors, LLC Company 18. Jul 19 18. Jul 19 -42,102 $163.27 $-6,873,994
19. Jul 19 Buy Citadel Advisors, LLC Company 18. Jul 19 18. Jul 19 46,316 $163.34 $7,565,255
19. Jul 19 Buy Northern Trust Global Investments Company 18. Jul 19 18. Jul 19 6,727 $162.58 $1,093,708
19. Jul 19 Sell Legg Mason, Inc. Company 18. Jul 19 18. Jul 19 -36 $162.70 $-5,857
19. Jul 19 Buy Legg Mason, Inc. Company 18. Jul 19 18. Jul 19 392 $162.39 $63,657
19. Jul 19 Sell T. Rowe Price Group, Inc. Company 18. Jul 19 18. Jul 19 -20,700 $162.88 $-3,371,699
19. Jul 19 Buy T. Rowe Price Group, Inc. Company 18. Jul 19 18. Jul 19 121 $162.48 $19,659
19. Jul 19 Sell Franklin Resources, Inc. Company 18. Jul 19 18. Jul 19 -508 $162.51 $-82,386
19. Jul 19 Sell Wellington Management Group LLP Company 18. Jul 19 18. Jul 19 -363,785 $162.98 $-59,088,366
19. Jul 19 Sell Longview Partners (Guernsey) Ltd Company 18. Jul 19 18. Jul 19 -110 $162.05 $-17,826
17. Jul 19 Sell BlackRock, Inc. Company 16. Jul 19 16. Jul 19 -2,695 $164.86 $-444,195
17. Jul 19 Buy BlackRock, Inc. Company 16. Jul 19 16. Jul 19 9,469 $164.99 $1,555,894
18. Jul 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 17. Jul 19 17. Jul 19 -39,891 $164.43 $-6,559,277
18. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 17. Jul 19 17. Jul 19 45,638 $164.82 $7,522,055
17. Jul 19 Sell Citadel Advisors, LLC Company 16. Jul 19 16. Jul 19 -50,049 $166.13 $-8,314,640
17. Jul 19 Buy Citadel Advisors, LLC Company 16. Jul 19 16. Jul 19 41,504 $166.18 $6,897,135
18. Jul 19 Sell Citadel Advisors, LLC Company 17. Jul 19 17. Jul 19 -54,519 $164.81 $-8,985,276
18. Jul 19 Buy Citadel Advisors, LLC Company 17. Jul 19 17. Jul 19 36,288 $164.81 $5,980,625
18. Jul 19 Sell FMR LLC Company 17. Jul 19 17. Jul 19 -114,715 $164.73 $-18,814,332
18. Jul 19 Buy FMR LLC Company 17. Jul 19 17. Jul 19 9,006 $164.38 $749,023
18. Jul 19 Sell BlackRock, Inc. Company 17. Jul 19 17. Jul 19 -10,277 $163.88 $-1,672,843
18. Jul 19 Buy BlackRock, Inc. Company 17. Jul 19 17. Jul 19 2,480 $164.28 $404,602
18. Jul 19 Sell Legg Mason, Inc. Company 17. Jul 19 17. Jul 19 -83 $163.87 $-13,601
18. Jul 19 Buy Legg Mason, Inc. Company 17. Jul 19 17. Jul 19 40 $163.92 $6,557
18. Jul 19 Sell Wellington Management Group LLP Company 17. Jul 19 17. Jul 19 -233,131 $164.37 $-38,256,765
18. Jul 19 Sell Northern Trust Global Investments Company 17. Jul 19 17. Jul 19 -8 $164.26 $-1,314
18. Jul 19 Buy Northern Trust Global Investments Company 17. Jul 19 17. Jul 19 11,743 $164.79 $1,935,129
18. Jul 19 Sell Franklin Resources, Inc. Company 17. Jul 19 17. Jul 19 -26,500 $164.13 $-4,349,445
18. Jul 19 Buy Franklin Resources, Inc. Company 17. Jul 19 17. Jul 19 5 $162.46 $812
18. Jul 19 Sell T. Rowe Price Group, Inc. Company 17. Jul 19 17. Jul 19 -691 $164.41 $-113,600
18. Jul 19 Buy T. Rowe Price Group, Inc. Company 17. Jul 19 17. Jul 19 22 $164.59 $3,621
18. Jul 19 Sell GIC Pte. Ltd. Company 17. Jul 19 17. Jul 19 -17,045 $162.46 $-2,769,131
17. Jul 19 Sell FMR LLC Company 16. Jul 19 16. Jul 19 -158,501 $165.89 $-26,072,755
17. Jul 19 Buy FMR LLC Company 16. Jul 19 16. Jul 19 5,451 $165.91 $904,286
17. Jul 19 Sell Legg Mason, Inc. Company 16. Jul 19 16. Jul 19 -26,811 $164.75 $-4,415,571
17. Jul 19 Buy Legg Mason, Inc. Company 16. Jul 19 16. Jul 19 41 $164.86 $6,759
17. Jul 19 Sell Franklin Resources, Inc. Company 16. Jul 19 16. Jul 19 -23,220 $164.41 $-3,817,600
17. Jul 19 Sell Northern Trust Global Investments Company 16. Jul 19 16. Jul 19 -83 $165.15 $-13,708
17. Jul 19 Buy Northern Trust Global Investments Company 16. Jul 19 16. Jul 19 11,683 $164.79 $1,925,242
17. Jul 19 Sell T. Rowe Price Group, Inc. Company 16. Jul 19 16. Jul 19 -19,900 $165.81 $-3,298,382
17. Jul 19 Buy T. Rowe Price Group, Inc. Company 16. Jul 19 16. Jul 19 61 $164.85 $10,056
17. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 16. Jul 19 16. Jul 19 101,051 $166.00 $16,774,466
17. Jul 19 Sell Wellington Management Group LLP Company 16. Jul 19 16. Jul 19 -246,379 $165.13 $-40,673,110
17. Jul 19 Buy Wellington Management Group LLP Company 16. Jul 19 16. Jul 19 21,791 $164.26 $3,579,390
17. Jul 19 Buy GIC Pte. Ltd. Company 16. Jul 19 16. Jul 19 150,000 $164.26 $24,639,000
16. Jul 19 Sell Wellington Management Group LLP Company 15. Jul 19 15. Jul 19 -1,430,051 $166.30 $-237,818,471
16. Jul 19 Sell FMR LLC Company 15. Jul 19 15. Jul 19 -71,779 $166.99 $-11,964,416
16. Jul 19 Buy FMR LLC Company 15. Jul 19 15. Jul 19 8,774 $166.73 $1,462,600
16. Jul 19 Sell Citadel Advisors, LLC Company 15. Jul 19 15. Jul 19 -37,481 $167.02 $-6,260,077
16. Jul 19 Buy Citadel Advisors, LLC Company 15. Jul 19 15. Jul 19 38,256 $167.05 $6,390,665
16. Jul 19 Sell BlackRock, Inc. Company 15. Jul 19 15. Jul 19 -2,588 $166.08 $-429,815
16. Jul 19 Buy BlackRock, Inc. Company 15. Jul 19 15. Jul 19 588 $166.08 $97,655
16. Jul 19 Sell Franklin Resources, Inc. Company 15. Jul 19 15. Jul 19 -8 $166.33 $-1,331
16. Jul 19 Sell T. Rowe Price Group, Inc. Company 15. Jul 19 15. Jul 19 -58,200 $166.08 $-9,665,914
16. Jul 19 Sell Northern Trust Global Investments Company 15. Jul 19 15. Jul 19 -589 $166.08 $-97,821
16. Jul 19 Buy Northern Trust Global Investments Company 15. Jul 19 15. Jul 19 5,762 $167.00 $0
16. Jul 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 15. Jul 19 15. Jul 19 -435,290 $166.99 $-72,689,077
16. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 15. Jul 19 15. Jul 19 422,599 $166.75 $70,468,383
16. Jul 19 Sell GIC Pte. Ltd. Company 15. Jul 19 15. Jul 19 -101,563 $166.75 $-16,935,630
16. Jul 19 Buy GIC Pte. Ltd. Company 15. Jul 19 15. Jul 19 114 $165.63 $18,882
15. Jul 19 Sell FMR LLC Company 12. Jul 19 12. Jul 19 -334,685 $165.54 $-55,336,050
15. Jul 19 Buy FMR LLC Company 12. Jul 19 12. Jul 19 13,734 $165.74 $2,270,261
15. Jul 19 Sell BlackRock, Inc. Company 12. Jul 19 12. Jul 19 -8,905 $165.85 $-1,471,416
15. Jul 19 Buy BlackRock, Inc. Company 12. Jul 19 12. Jul 19 1,388 $165.85 $229,916
15. Jul 19 Sell Legg Mason, Inc. Company 12. Jul 19 12. Jul 19 -34 $165.74 $-5,635
15. Jul 19 Buy Legg Mason, Inc. Company 12. Jul 19 12. Jul 19 23 $165.34 $3,803
15. Jul 19 Sell Northern Trust Global Investments Company 12. Jul 19 12. Jul 19 -430 $165.61 $-71,212
15. Jul 19 Buy Northern Trust Global Investments Company 12. Jul 19 12. Jul 19 1,154 $165.85 $191,124
15. Jul 19 Sell Citadel Advisors, LLC Company 12. Jul 19 12. Jul 19 -41,223 $165.98 $-6,842,194
15. Jul 19 Buy Citadel Advisors, LLC Company 12. Jul 19 12. Jul 19 96,178 $166.22 $15,986,707
15. Jul 19 Sell T. Rowe Price Group, Inc. Company 12. Jul 19 12. Jul 19 -165 $165.85 $-27,319
15. Jul 19 Buy T. Rowe Price Group, Inc. Company 12. Jul 19 12. Jul 19 33,620 $165.71 $5,561,813
15. Jul 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 12. Jul 19 12. Jul 19 -114,083 $165.97 $-18,934,356
15. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 12. Jul 19 12. Jul 19 237,887 $166.07 $39,505,894
15. Jul 19 Sell Franklin Resources, Inc. Company 12. Jul 19 12. Jul 19 -1 $165.85 $-166
15. Jul 19 Sell Wellington Management Group LLP Company 12. Jul 19 12. Jul 19 -528,169 $165.85 $-87,309,296
11. Jul 19 Sell Citadel Advisors, LLC Company 10. Jul 19 10. Jul 19 -58,186 $167.14 $-9,725,208
11. Jul 19 Buy Citadel Advisors, LLC Company 10. Jul 19 10. Jul 19 160,003 $167.24 $26,758,902
12. Jul 19 Sell Citadel Advisors, LLC Company 11. Jul 19 11. Jul 19 -34,354 $167.25 $-5,745,707
12. Jul 19 Buy Citadel Advisors, LLC Company 11. Jul 19 11. Jul 19 44,273 $167.04 $7,395,362
12. Jul 19 Sell BlackRock, Inc. Company 11. Jul 19 11. Jul 19 -1,787 $166.17 $-296,603
12. Jul 19 Buy BlackRock, Inc. Company 11. Jul 19 11. Jul 19 969 $166.30 $160,894
12. Jul 19 Sell FMR LLC Company 11. Jul 19 11. Jul 19 -224,407 $166.81 $-37,296,858
12. Jul 19 Buy FMR LLC Company 11. Jul 19 11. Jul 19 18,634 $166.98 $3,099,305
12. Jul 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 11. Jul 19 11. Jul 19 -17,712 $166.67 $-2,952,059
12. Jul 19 Sell Northern Trust Global Investments Company 11. Jul 19 11. Jul 19 -95 $166.41 $-15,809
12. Jul 19 Buy Northern Trust Global Investments Company 11. Jul 19 11. Jul 19 4,144 $166.21 $688,774
12. Jul 19 Sell Legg Mason, Inc. Company 11. Jul 19 11. Jul 19 -37 $166.23 $-6,151
12. Jul 19 Buy Legg Mason, Inc. Company 11. Jul 19 11. Jul 19 109 $165.98 $18,092
12. Jul 19 Sell Franklin Resources, Inc. Company 11. Jul 19 11. Jul 19 -4 $165.97 $-664
12. Jul 19 Sell Wellington Management Group LLP Company 11. Jul 19 11. Jul 19 -192 $166.08 $-31,873
12. Jul 19 Buy Wellington Management Group LLP Company 11. Jul 19 11. Jul 19 2,901 $165.93 $481,369
12. Jul 19 Buy T. Rowe Price Group, Inc. Company 11. Jul 19 11. Jul 19 102 $166.78 $17,012
12. Jul 19 Buy Longview Partners (Guernsey) Ltd Company 11. Jul 19 11. Jul 19 500 $165.97 $82,985
12. Jul 19 Sell GIC Pte. Ltd. Company 11. Jul 19 11. Jul 19 -231,564 $166.85 $-38,623,590
11. Jul 19 Sell Northern Trust Global Investments Company 10. Jul 19 10. Jul 19 -26 $166.72 $-4,335
11. Jul 19 Buy Northern Trust Global Investments Company 10. Jul 19 10. Jul 19 122 $167.00 $20,365
11. Jul 19 Sell Wellington Management Group LLP Company 09. Jul 19 09. Jul 19 -26,441 $166.91 $-4,409,906
11. Jul 19 Buy Wellington Management Group LLP Company 09. Jul 19 09. Jul 19 13,561 $166.74 $2,261,224
11. Jul 19 Sell Citadel Advisors, LLC Company 09. Jul 19 09. Jul 19 -43,680 $167.59 $-7,320,331
11. Jul 19 Buy Citadel Advisors, LLC Company 09. Jul 19 09. Jul 19 57,920 $167.46 $9,699,283
11. Jul 19 Sell FMR LLC Company 10. Jul 19 10. Jul 19 -44 $166.93 $-7,343
11. Jul 19 Buy FMR LLC Company 10. Jul 19 10. Jul 19 206,371 $167.11 $34,439,216
11. Jul 19 Sell BlackRock, Inc. Company 10. Jul 19 10. Jul 19 -10,197 $166.91 $-1,701,789
11. Jul 19 Buy BlackRock, Inc. Company 10. Jul 19 10. Jul 19 4,230 $166.74 $705,139
11. Jul 19 Sell Legg Mason, Inc. Company 10. Jul 19 10. Jul 19 -2 $167.21 $-334
11. Jul 19 Buy Legg Mason, Inc. Company 10. Jul 19 10. Jul 19 210 $166.82 $35,032
11. Jul 19 Sell Citadel Advisors, LLC Company 08. Jul 19 08. Jul 19 -93,756 $167.65 $-15,718,193
11. Jul 19 Buy Citadel Advisors, LLC Company 08. Jul 19 08. Jul 19 378,299 $167.69 $63,436,959
11. Jul 19 Sell Franklin Resources, Inc. Company 10. Jul 19 10. Jul 19 -20 $166.99 $-3,340
11. Jul 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 10. Jul 19 10. Jul 19 -30,735 $167.03 $-5,133,667
11. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 10. Jul 19 10. Jul 19 208,461 $167.29 $34,873,441
11. Jul 19 Sell GIC Pte. Ltd. Company 10. Jul 19 10. Jul 19 -400,182 $166.92 $-66,798,379
10. Jul 19 Sell Northern Trust Global Investments Company 09. Jul 19 09. Jul 19 -249 $167.37 $-41,675
10. Jul 19 Buy Northern Trust Global Investments Company 09. Jul 19 09. Jul 19 3,189 $167.40 $533,839
10. Jul 19 Sell Legg Mason, Inc. Company 09. Jul 19 09. Jul 19 -10 $166.75 $-1,668
10. Jul 19 Buy Legg Mason, Inc. Company 09. Jul 19 09. Jul 19 66 $167.40 $11,048
10. Jul 19 Sell BlackRock, Inc. Company 09. Jul 19 09. Jul 19 -2,487 $166.45 $-413,961
10. Jul 19 Buy BlackRock, Inc. Company 09. Jul 19 09. Jul 19 15,920 $167.26 $2,656,738
10. Jul 19 Sell FMR LLC Company 09. Jul 19 09. Jul 19 -155,209 $167.28 $-25,889,929
10. Jul 19 Buy FMR LLC Company 09. Jul 19 09. Jul 19 5,204 $167.25 $870,369
10. Jul 19 Sell T. Rowe Price Group, Inc. Company 09. Jul 19 09. Jul 19 -2,711 $167.28 $-451,784
10. Jul 19 Buy Franklin Resources, Inc. Company 09. Jul 19 09. Jul 19 110 $166.55 $18,321
10. Jul 19 Sell GIC Pte. Ltd. Company 09. Jul 19 09. Jul 19 -290,031 $167.00 $-48,435,177
10. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 09. Jul 19 09. Jul 19 293,375 $167.58 $49,163,783
10. Jul 19 Buy Longview Partners (Guernsey) Ltd Company 09. Jul 19 09. Jul 19 10,100 $166.45 $1,681,145
09. Jul 19 Sell GIC Pte. Ltd. Company 08. Jul 19 08. Jul 19 -249,398 $165.90 $-41,374,604
09. Jul 19 Sell Wellington Management Group LLP Company 08. Jul 19 08. Jul 19 -5,905 $165.57 $-977,529
09. Jul 19 Sell FMR LLC Company 08. Jul 19 08. Jul 19 -245,575 $167.29 $-40,689,525
09. Jul 19 Buy FMR LLC Company 08. Jul 19 08. Jul 19 11,576 $167.43 $1,923,625
09. Jul 19 Sell Legg Mason, Inc. Company 08. Jul 19 08. Jul 19 -75,378 $166.55 $-12,554,206
09. Jul 19 Buy Legg Mason, Inc. Company 08. Jul 19 08. Jul 19 70 $166.15 $11,631
09. Jul 19 Sell BlackRock, Inc. Company 08. Jul 19 08. Jul 19 -967 $164.95 $-159,507
09. Jul 19 Buy BlackRock, Inc. Company 08. Jul 19 08. Jul 19 1,225 $167.63 $202,267
09. Jul 19 Sell Northern Trust Global Investments Company 08. Jul 19 08. Jul 19 -14,349 $165.51 $-2,374,903
09. Jul 19 Buy Northern Trust Global Investments Company 08. Jul 19 08. Jul 19 6,379 $165.79 $1,057,574
09. Jul 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 08. Jul 19 08. Jul 19 -59,525 $167.29 $-9,957,937
09. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 08. Jul 19 08. Jul 19 86,415 $167.66 $14,488,339
09. Jul 19 Sell Franklin Resources, Inc. Company 08. Jul 19 08. Jul 19 -14,630 $166.01 $-2,425,958
09. Jul 19 Buy Franklin Resources, Inc. Company 08. Jul 19 08. Jul 19 349,105 $166.21 $57,935,941
09. Jul 19 Buy T. Rowe Price Group, Inc. Company 08. Jul 19 08. Jul 19 740 $166.43 $123,157
08. Jul 19 Sell Legg Mason, Inc. Company 05. Jul 19 05. Jul 19 -9 $168.49 $-1,516
08. Jul 19 Buy Legg Mason, Inc. Company 05. Jul 19 05. Jul 19 2 $168.59 $337
08. Jul 19 Sell BlackRock, Inc. Company 05. Jul 19 05. Jul 19 -474 $167.69 $-79,485
08. Jul 19 Buy BlackRock, Inc. Company 05. Jul 19 05. Jul 19 3,532 $167.69 $592,281
08. Jul 19 Sell FMR LLC Company 05. Jul 19 05. Jul 19 -59,715 $168.91 $-10,014,303
08. Jul 19 Buy FMR LLC Company 05. Jul 19 05. Jul 19 18,001 $169.03 $3,037,066
08. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 05. Jul 19 05. Jul 19 162,578 $168.92 $27,462,676
08. Jul 19 Buy T. Rowe Price Group, Inc. Company 05. Jul 19 05. Jul 19 61 $169.08 $10,314
08. Jul 19 Buy Franklin Resources, Inc. Company 05. Jul 19 05. Jul 19 179,301 $168.80 $30,266,009
08. Jul 19 Sell GIC Pte. Ltd. Company 05. Jul 19 05. Jul 19 -420,541 $169.05 $-70,928,915
08. Jul 19 Buy Longview Partners (Guernsey) Ltd Company 05. Jul 19 05. Jul 19 3,500 $167.69 $586,915
08. Jul 19 Sell Wellington Management Group LLP Company 05. Jul 19 05. Jul 19 -689 $169.00 $-116,382
05. Jul 19 Buy Franklin Resources, Inc. Company 03. Jul 19 03. Jul 19 250,000 $169.37 $42,338,000
04. Jul 19 Sell FMR LLC Company 03. Jul 19 03. Jul 19 -242 $169.38 $-40,990
04. Jul 19 Buy FMR LLC Company 03. Jul 19 03. Jul 19 2,686 $169.40 $455,008
04. Jul 19 Sell Legg Mason, Inc. Company 03. Jul 19 03. Jul 19 -43 $169.41 $-7,285
04. Jul 19 Buy Legg Mason, Inc. Company 03. Jul 19 03. Jul 19 998 $169.50 $169,161
04. Jul 19 Sell Northern Trust Global Investments Company 02. Jul 19 02. Jul 19 -875 $169.56 $-148,365
04. Jul 19 Buy Northern Trust Global Investments Company 02. Jul 19 02. Jul 19 1,786 $169.61 $302,923
04. Jul 19 Sell BlackRock, Inc. Company 03. Jul 19 03. Jul 19 -12,025 $169.61 $-2,039,077
04. Jul 19 Buy BlackRock, Inc. Company 03. Jul 19 03. Jul 19 1,085 $169.61 $184,027
04. Jul 19 Sell T. Rowe Price Group, Inc. Company 03. Jul 19 03. Jul 19 -20,600 $169.46 $-3,490,897
04. Jul 19 Buy T. Rowe Price Group, Inc. Company 03. Jul 19 03. Jul 19 616 $169.22 $104,236
04. Jul 19 Sell Wellington Management Group LLP Company 03. Jul 19 03. Jul 19 -125,730 $169.61 $-21,320,152
04. Jul 19 Sell GIC Pte. Ltd. Company 03. Jul 19 03. Jul 19 -408,837 $169.52 $-69,285,746
04. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 03. Jul 19 03. Jul 19 46,494 $169.73 $7,891,427
03. Jul 19 Sell T. Rowe Price Group, Inc. Company 02. Jul 19 02. Jul 19 -300 $168.50 $-50,551
03. Jul 19 Buy T. Rowe Price Group, Inc. Company 02. Jul 19 02. Jul 19 621,332 $169.98 $105,322,644
03. Jul 19 Sell Franklin Resources, Inc. Company 02. Jul 19 02. Jul 19 -1,684 $169.54 $-283,546
03. Jul 19 Buy Franklin Resources, Inc. Company 02. Jul 19 02. Jul 19 152,869 $169.42 $25,807,150
03. Jul 19 Sell BlackRock, Inc. Company 02. Jul 19 02. Jul 19 -2,327 $169.54 $-394,520
03. Jul 19 Buy BlackRock, Inc. Company 02. Jul 19 02. Jul 19 10,504 $169.54 $1,777,349
03. Jul 19 Sell Northern Trust Global Investments Company 02. Jul 19 02. Jul 19 -1,458 $169.54 $-247,189
03. Jul 19 Buy Northern Trust Global Investments Company 02. Jul 19 02. Jul 19 1,947 $169.82 $330,640
03. Jul 19 Sell FMR LLC Company 02. Jul 19 02. Jul 19 -59 $168.17 $-9,912
03. Jul 19 Buy FMR LLC Company 02. Jul 19 02. Jul 19 104,748 $169.53 $17,584,283
03. Jul 19 Sell Wellington Management Group LLP Company 02. Jul 19 02. Jul 19 -50,899 $169.76 $-8,528,389
03. Jul 19 Buy Wellington Management Group LLP Company 02. Jul 19 02. Jul 19 27,900 $169.54 $4,704,697
03. Jul 19 Sell Legg Mason, Inc. Company 02. Jul 19 02. Jul 19 -1 $169.36 $-169
03. Jul 19 Buy Legg Mason, Inc. Company 02. Jul 19 02. Jul 19 3 $169.40 $508
03. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 02. Jul 19 02. Jul 19 40,708 $170.13 $6,925,449
03. Jul 19 Sell GIC Pte. Ltd. Company 02. Jul 19 02. Jul 19 -265,546 $170.06 $-44,958,552
02. Jul 19 Sell FMR LLC Company 01. Jul 19 01. Jul 19 -329 $168.15 $-55,234
02. Jul 19 Buy FMR LLC Company 01. Jul 19 01. Jul 19 14,051 $168.42 $2,353,413
02. Jul 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 01. Jul 19 01. Jul 19 -69,602 $168.30 $-11,714,017
02. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 01. Jul 19 01. Jul 19 338,332 $168.60 $57,042,775
02. Jul 19 Sell Wellington Management Group LLP Company 01. Jul 19 01. Jul 19 -555,153 $167.97 $-93,019,260
02. Jul 19 Sell Northern Trust Global Investments Company 01. Jul 19 01. Jul 19 -8,819 $168.00 $-1,481,592
02. Jul 19 Buy Northern Trust Global Investments Company 01. Jul 19 01. Jul 19 5,351 $167.99 $898,914
02. Jul 19 Sell BlackRock, Inc. Company 01. Jul 19 01. Jul 19 -62,208 $167.71 $-10,393,987
02. Jul 19 Buy BlackRock, Inc. Company 01. Jul 19 01. Jul 19 4,417 $167.77 $739,885
02. Jul 19 Sell Legg Mason, Inc. Company 01. Jul 19 01. Jul 19 -80,006 $167.42 $-13,394,605
02. Jul 19 Buy Legg Mason, Inc. Company 01. Jul 19 01. Jul 19 2 $167.55 $335
02. Jul 19 Sell Franklin Resources, Inc. Company 01. Jul 19 01. Jul 19 -2,175 $167.99 $-365,378
02. Jul 19 Buy Franklin Resources, Inc. Company 01. Jul 19 01. Jul 19 50,115 $167.98 $8,400,818
02. Jul 19 Sell GIC Pte. Ltd. Company 01. Jul 19 01. Jul 19 -253,964 $167.97 $-42,589,708
02. Jul 19 Sell Longview Partners (Guernsey) Ltd Company 01. Jul 19 01. Jul 19 -6,400 $167.52 $-1,072,128
02. Jul 19 Buy Longview Partners (Guernsey) Ltd Company 01. Jul 19 01. Jul 19 6,800 $167.52 $1,139,136
01. Jul 19 Sell Legg Mason, Inc. Company 28. Jun 19 28. Jun 19 -80,000 $167.54 $-13,403,200
01. Jul 19 Sell FMR LLC Company 28. Jun 19 28. Jun 19 -535,454 $167.43 $-89,562,101
01. Jul 19 Buy FMR LLC Company 28. Jun 19 28. Jun 19 59,360 $167.94 $9,934,038
01. Jul 19 Buy Northern Trust Global Investments Company 28. Jun 19 28. Jun 19 3,593 $167.49 $601,792
01. Jul 19 Sell BlackRock, Inc. Company 28. Jun 19 28. Jun 19 -258,627 $167.85 $-43,302,897
01. Jul 19 Buy BlackRock, Inc. Company 28. Jun 19 28. Jun 19 41,746 $167.47 $6,989,730
01. Jul 19 Sell Franklin Resources, Inc. Company 28. Jun 19 28. Jun 19 -1,100 $167.09 $-183,799
01. Jul 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 28. Jun 19 28. Jun 19 -385,835 $167.83 $-64,754,688
01. Jul 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 28. Jun 19 28. Jun 19 697,219 $168.14 $117,230,403
01. Jul 19 Sell Wellington Management Group LLP Company 28. Jun 19 28. Jun 19 -77,515 $167.43 $-4,112,444
01. Jul 19 Sell GIC Pte. Ltd. Company 28. Jun 19 28. Jun 19 -204,252 $167.62 $-34,180,175
01. Jul 19 Buy GIC Pte. Ltd. Company 28. Jun 19 28. Jun 19 146 $167.41 $24,442
28. Jun 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 27. Jun 19 27. Jun 19 100,976 $167.39 $16,902,373
28. Jun 19 Sell Legg Mason, Inc. Company 27. Jun 19 27. Jun 19 -55 $166.48 $-9,156
28. Jun 19 Buy Legg Mason, Inc. Company 27. Jun 19 27. Jun 19 421 $166.37 $70,042
28. Jun 19 Sell BlackRock, Inc. Company 27. Jun 19 27. Jun 19 -1,769 $166.01 $-293,672
28. Jun 19 Buy BlackRock, Inc. Company 27. Jun 19 27. Jun 19 2,585 $166.06 $429,199
28. Jun 19 Sell FMR LLC Company 27. Jun 19 27. Jun 19 -131,505 $167.25 $-21,924,732
28. Jun 19 Buy FMR LLC Company 27. Jun 19 27. Jun 19 107,602 $166.74 $17,917,571
28. Jun 19 Sell Columbia Management Investment Advisers, LLC Company 27. Jun 19 27. Jun 19 -28 $166.01 $-4,648
28. Jun 19 Buy Columbia Management Investment Advisers, LLC Company 27. Jun 19 27. Jun 19 75 $166.01 $12,451
28. Jun 19 Sell Franklin Resources, Inc. Company 27. Jun 19 27. Jun 19 -5,186 $166.47 $-863,285
28. Jun 19 Sell Wellington Management Group LLP Company 27. Jun 19 27. Jun 19 -17,694 $166.80 $-2,944,236
28. Jun 19 Buy Wellington Management Group LLP Company 27. Jun 19 27. Jun 19 25,946 $166.89 $4,330,169
28. Jun 19 Sell GIC Pte. Ltd. Company 27. Jun 19 27. Jun 19 -304,808 $166.48 $-50,743,979
27. Jun 19 Sell FMR LLC Company 26. Jun 19 26. Jun 19 -1,147,433 $165.03 $-188,817,024
27. Jun 19 Buy FMR LLC Company 26. Jun 19 26. Jun 19 5,497 $164.69 $904,972
27. Jun 19 Sell Legg Mason, Inc. Company 26. Jun 19 26. Jun 19 -425 $164.49 $-69,908
27. Jun 19 Buy Legg Mason, Inc. Company 26. Jun 19 26. Jun 19 350 $164.63 $57,621
27. Jun 19 Sell Columbia Management Investment Advisers, LLC Company 26. Jun 19 26. Jun 19 -23,672 $164.03 $-3,882,209
27. Jun 19 Buy Columbia Management Investment Advisers, LLC Company 26. Jun 19 26. Jun 19 3,772 $164.00 $618,608
27. Jun 19 Sell BlackRock, Inc. Company 26. Jun 19 26. Jun 19 -104,799 $164.72 $-17,250,016
27. Jun 19 Buy BlackRock, Inc. Company 26. Jun 19 26. Jun 19 38,025 $164.66 $6,246,537
27. Jun 19 Sell Goldman Sachs Group, Investment Banking and Securities Investments Company 26. Jun 19 26. Jun 19 -929,383 $165.13 $-153,469,015
27. Jun 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 26. Jun 19 26. Jun 19 664,120 $165.11 $109,652,853
27. Jun 19 Buy Franklin Resources, Inc. Company 26. Jun 19 26. Jun 19 150 $164.31 $24,647
27. Jun 19 Sell GIC Pte. Ltd. Company 26. Jun 19 26. Jun 19 -53,070 $164.97 $-8,755,213
27. Jun 19 Sell Wellington Management Group LLP Company 26. Jun 19 26. Jun 19 -10,321 $164.70 $-1,699,882
27. Jun 19 Buy Wellington Management Group LLP Company 26. Jun 19 26. Jun 19 3,655 $163.84 $598,835
26. Jun 19 Sell Columbia Management Investment Advisers, LLC Company 25. Jun 19 25. Jun 19 -300,947 $162.46 $-48,882,899
26. Jun 19 Buy Columbia Management Investment Advisers, LLC Company 25. Jun 19 25. Jun 19 15,626 $162.43 $2,538,131
26. Jun 19 Sell Franklin Resources, Inc. Company 25. Jun 19 25. Jun 19 -62,900 $163.38 $-10,276,602
26. Jun 19 Sell BlackRock, Inc. Company 25. Jun 19 25. Jun 19 -946,003 $165.10 $-155,389,494
26. Jun 19 Buy BlackRock, Inc. Company 25. Jun 19 25. Jun 19 75,000 $166.50 $12,308,155
26. Jun 19 Sell Wellington Management Group LLP Company 25. Jun 19 25. Jun 19 -1,207,252 $168.37 $-198,357,574
26. Jun 19 Buy Wellington Management Group LLP Company 25. Jun 19 25. Jun 19 1,659 $129.57 $214,957
26. Jun 19 Sell GIC Pte. Ltd. Company 25. Jun 19 25. Jun 19 -416,612 $164.27 $-68,299,406
07. Mar 19 Buy Brenton Saunders Individual 07. Mar 19 07. Mar 19 1,760 $144.37 $252,858
20. Nov 18 Buy Matthew Walsh Individual 16. Nov 18 16. Nov 18 1,000 $157.00 $157,000
07. Sep 18 Buy Christopher Coughlin Individual 06. Sep 18 06. Sep 18 10,000 $190.68 $1,906,394
04. Sep 18 Sell Nesli Basgoz Individual 30. Aug 18 30. Aug 18 -1,055 $190.05 $-200,503
04. Sep 18 Buy Joseph Boccuzi Individual 30. Aug 18 30. Aug 18 900 $190.59 $171,531
04. Sep 18 Buy Thomas Freyman Individual 30. Aug 18 30. Aug 18 1,100 $190.69 $209,759
X
Management checks
We assess Allergan's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Allergan has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did Allergan plc (NYSE:AGN) Insiders Buy Up More Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for Allergan Allergan Insider Transactions Over The Last Year Lead Independent Director Christopher Coughlin made the biggest insider purchase in the last 12 months. … Insider Ownership of Allergan Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. … With high insider ownership and encouraging transactions, it seems like Allergan insiders think the business has merit.

Simply Wall St -

Are Insiders Buying Allergan plc (NYSE:AGN) Stock?

See our latest analysis for Allergan Allergan Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Lead Independent Director Christopher Coughlin for US$1.9m worth of shares, at about US$191 per share. … NYSE:AGN Recent Insider Trading, June 25th 2019 Allergan is not the only stock insiders are buying. … It would be great to see more insider buying, but overall it seems like Allergan insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future.

Simply Wall St -

Volatility 101: Should Allergan (NYSE:AGN) Shares Have Dropped 34%?

We regret to report that long term Allergan plc (NYSE:AGN) shareholders have had that experience, with the share price dropping 34% in three years, versus a market return of about 53%. … Given that Allergan didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Over three years, Allergan grew revenue at 6.6% per year.

Simply Wall St -

Is Allergan plc (NYSE:AGN) Excessively Paying Its CEO?

First, this article will compare CEO compensation with compensation at other large companies. … How Does Brent Saunders's Compensation Compare With Similar Sized Companies. … Our data indicates that Allergan plc is worth US$48b, and total annual CEO compensation is US$33m.

Simply Wall St -

Zooming in on NYSE:AGN's 2.0% Dividend Yield

Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. … Allergan plc (NYSE:AGN) has recently paid dividends to shareholders, and currently yields 2.0%. … Let's dig deeper into whether Allergan should have a place in your portfolio.

Simply Wall St -

Has Allergan plc (NYSE:AGN) Got Enough Cash?

Most investors favour these big stocks due to their strong balance sheet and high market liquidity, meaning there are an abundance of stock in the public market available for trading. … These firms won’t be left high and dry if liquidity dries up, and they will be relatively unaffected by rises in interest rates. … Today I will analyse the latest financial data for AGN to determine is solvency and liquidity and whether the stock is a sound investment.

Simply Wall St -

Need To Know: Allergan plc (NYSE:AGN) Insiders Have Been Selling Shares

So shareholders might well want to know whether insiders have been buying or selling shares in Allergan plc (NYSE:AGN). … We don't think shareholders should simply follow insider transactions. … So we know that an insider sold shares at around the present share price of US$139

Simply Wall St -

Investors Are Undervaluing Allergan plc (NYSE:AGN) By 49.32%

by taking the expected future cash flows and discounting them to today's value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Is Allergan plc (NYSE:AGN) A Great Dividend Stock?

In the last few years Allergan plc (NYSE:AGN) has paid a dividend to shareholders. … Does Allergan tick all the boxes of a great dividend stock? … 5 questions to ask before buying a dividend stock

Simply Wall St -

Interested In Allergan plc (NYSE:AGN)’s Upcoming US$0.72 Dividend? You Have 4 Days Left

On the 14 December 2018, Allergan plc (NYSE:AGN) will be paying shareholders an upcoming dividend amount of US$0.72 per share. … Is this future income stream a compelling catalyst for dividend investors to think about the stock as an investment today? … Has it paid dividend every year without dramatically reducing payout in the past?

Simply Wall St -

Company Info

Description

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women’s health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Details
Name: Allergan plc
AGN
Exchange: NYSE
Founded: 1983
$53,071,411,656
327,823,903
Website: http://www.allergan.com
Address: Allergan plc
Clonshaugh Business and Technology Park,
Coolock,
Dublin,
Co. Dublin, D17 E400,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE AGN Common Stock New York Stock Exchange US USD 17. Feb 1993
DB A60 Common Stock Deutsche Boerse AG DE EUR 17. Feb 1993
LSE 0Y7T Common Stock London Stock Exchange GB USD 17. Feb 1993
BMV AGN N Common Stock Bolsa Mexicana de Valores MX MXN 17. Feb 1993
BASE AGN CEDEAR EACH 8 REP 1 COM USD0.0001 Buenos Aires Stock Exchange AR ARS 12. Apr 2019
Number of employees
Current staff
Staff numbers
16,900
Allergan employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/24 02:42
End of day share price update: 2019/07/23 00:00
Last estimates confirmation: 2019/07/22
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.